Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation by De Stefano, Daniela et al.
                                                              
University of Dundee
Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-
CFTR mutation
De Stefano, Daniela ; Villella, Valeria R.; Esposito, Speranza; Tosco, Antonella; Sepe,
Angela; De Gregorio, Fabiola; Salvadori, Laura; Grassia, Rosa; Leone, Carlo A.; De Rosa,
Giuseppe; Maiuri, Maria C.; Pettoello-Mantovani, Massimo; Guido, Stefano; Bossi, Anna;
Zolin, Anna; Venerando, Andrea; Pinna, Lorenzo A.; Mehta, Anil; Bona, Gianni; Kroemer,
Guido; Maiuri, Luigi; Raia, Valeria
Published in:
Autophagy
DOI:
10.4161/15548627.2014.973737
Publication date:
2014
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
De Stefano, D., Villella, V. R., Esposito, S., Tosco, A., Sepe, A., De Gregorio, F., ... Raia, V. (2014). Restoration
of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy, 10(11), 2053-
2074. 10.4161/15548627.2014.973737
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=kaup20
Download by: [University of Dundee] Date: 27 January 2016, At: 08:37
Autophagy
ISSN: 1554-8627 (Print) 1554-8635 (Online) Journal homepage: http://www.tandfonline.com/loi/kaup20
Restoration of CFTR function in patients with cystic
fibrosis carrying the F508del-CFTR mutation
Daniela De Stefano, Valeria R Villella, Speranza Esposito, Antonella Tosco,
Angela Sepe, Fabiola De Gregorio, Laura Salvadori, Rosa Grassia, Carlo A
Leone, Giuseppe De Rosa, Maria C Maiuri, Massimo Pettoello-Mantovani,
Stefano Guido, Anna Bossi, Anna Zolin, Andrea Venerando, Lorenzo A Pinna,
Anil Mehta, Gianni Bona, Guido Kroemer, Luigi Maiuri & Valeria Raia
To cite this article: Daniela De Stefano, Valeria R Villella, Speranza Esposito, Antonella Tosco,
Angela Sepe, Fabiola De Gregorio, Laura Salvadori, Rosa Grassia, Carlo A Leone, Giuseppe De
Rosa, Maria C Maiuri, Massimo Pettoello-Mantovani, Stefano Guido, Anna Bossi, Anna Zolin,
Andrea Venerando, Lorenzo A Pinna, Anil Mehta, Gianni Bona, Guido Kroemer, Luigi Maiuri
& Valeria Raia (2014) Restoration of CFTR function in patients with cystic fibrosis carrying the
F508del-CFTR mutation, Autophagy, 10:11, 2053-2074, DOI: 10.4161/15548627.2014.973737
To link to this article:  http://dx.doi.org/10.4161/15548627.2014.973737
© 2014 The Author(s). Published with
license by Taylor & Francis© Daniele De
Stefano, Valeria R Villella, Speranza Esposito,
Antonella Tosco, Angela Sepe, Fabiola De
Gregorio, Laura Salvadori, Rosa Grassia,
Carlo A Leone, Giuseppe De Rosa, Maria
C Maiuri, Massimo Pettoello-Mantovani,
Stefano Guido, Anna Bossi, Anna Zolin,
Andrea Venerando, Lorenzo A Pinna, Anil
Mehta, Gianni Bona, Guido Kroemer, Luigi
Maiuri, and Valeria Raia
View supplementary material 
Accepted author version posted online: 27
Oct 2014.
Submit your article to this journal 
Article views: 3233 View related articles 
View Crossmark data Citing articles: 14 View citing articles 
Restoration of CFTR function in patients with
cystic fibrosis carrying the F508del-CFTR mutation
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Abbreviations: BECN1/Beclin 1, autophagy-related; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator;
CHX, cycloheximide; CSNK2, casein kinase 2; CXCL2, chemokine (C-X-C motif) ligand 2; CXCL8, chemokine (C-X-C motif)
ligand 8; EGCG, epigallocatechin gallate; FEV, forced expiratory volume; PM, plasma membrane; RPD, rectal potential difference;
SQSTM1, sequestosome 1; TGM2, transglutaminase 2; TNF, tumor necrosis factor.
Restoration of BECN1/Beclin 1-dependent autophagy and depletion of SQSTM1/p62 by genetic manipulation or
autophagy-stimulatory proteostasis regulators, such as cystamine, have positive effects on mouse models of human
cystic fibrosis (CF). These measures rescue the functional expression of the most frequent pathogenic CFTR mutant,
F508del, at the respiratory epithelial surface and reduce lung inflammation in CftrF508del homozygous mice. Cysteamine,
the reduced form of cystamine, is an FDA-approved drug. Here, we report that oral treatment with cysteamine greatly
reduces the mortality rate and improves the phenotype of newborn mice bearing the F508del-CFTR mutation.
Cysteamine was also able to increase the plasma membrane expression of the F508del-CFTR protein in nasal epithelial
cells from F508del homozygous CF patients, and these effects persisted for 24 h after cysteamine withdrawal.
Importantly, this cysteamine effect after washout was further sustained by the sequential administration of
epigallocatechin gallate (EGCG), a green tea flavonoid, both in vivo, in mice, and in vitro, in primary epithelial cells from
CF patients. In a pilot clinical trial involving 10 F508del-CFTR homozygous CF patients, the combination of cysteamine
and EGCG restored BECN1, reduced SQSTM1 levels and improved CFTR function from nasal epithelial cells in vivo,
correlating with a decrease of chloride concentrations in sweat, as well as with a reduction of the abundance of TNF/
TNF-alpha (tumor necrosis factor) and CXCL8 (chemokine [C-X-C motif] ligand 8) transcripts in nasal brushing and TNF and
CXCL8 protein levels in the sputum. Altogether, these results suggest that optimal schedules of cysteamine plus EGCG
might be used for the treatment of CF caused by the F508del-CFTR mutation.
Introduction
Cystic fibrosis (CF), the most common lethal monogenic disease
in Caucasians, is caused by mutations in the gene coding for cystic
fibrosis transmembrane conductance regulator (CFTR), a 1480
amino-acid protein functioning as a chloride channel at apical mem-
brane from epithelial cells.1-3 CF is a systemic disease although the
extent of clinical manifestations is highly heterogeneous in distinct
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organs.4,5 CF-associated bronchopulmonary disease, the principal
cause of morbidity and mortality, comprises a compendium of alter-
ations including airway obstruction by viscous mucus and chronic
inflammation with recurrent bacterial infections, mainly by Pseudo-
monas aeruginosa. Other prevalent features of CF are insufficiency of
the exocrine pancreas, increased electrolytes in sweat, andmale infer-
tility. To date, the clinical management of CF focuses on treating
CF symptoms, yet fails to address the primary cause of CF, namely
the loss-of-function of CFTR. Therapeutic strategies aimed at cor-
recting the CFTR defect (“CFTR-repair”) have recently emerged.6
In the CFTR gene, more than 1,900 mutations, mostly dis-
ease-relevant, have been identified and then categorized in 6 dif-
ferent classes according to their functional impact.6,7 To treat the
phenotypic consequences of such genotypes, mutation-specific
approaches are focusing on the identification of small molecules
capable of correcting the deficient trafficking of the CFTR pro-
tein (“correctors”: agents that assure the expression of the
mutated protein in the apical plasma membrane) or defective gat-
ing (“potentiators”: agents that reinstate the electrolyte pump
function of mutated CFTR proteins that are orthotopically
expressed). An orally available compound identified by high-
throughput screening, the CFTR potentiator VX-770 (Ivacaftor,
trade name Kalydeco, Vertex Pharmaceuticals), efficiently
reduces chloride levels in sweat and improves lung function in
CF patients harboring the CFTRG551D genotype, a rare class III
CFTR mutant that affects only 4% to 5% of CF patients
worldwide.8
One single mutation, p.phe508delCFTR, commonly known as
F508del-CFTR (categorized in class II), accounts for about 70%
of CFTR loss-of-function mutations and is present in approxi-
mately 90% of CF patients worldwide.3,9 Due to its misfold,
F508del-CFTR protein does not reach the plasma membrane
(PM) and is prematurely degraded. Although F508del-CFTR
can be rescued at the PM by CFTR correctors,6 this mutant
CFTR protein is unstable at the cell surface and rapidly redir-
ected from endosomal recycling towards lysosomal delivery and
degradation.6,10,11
Despite of the mild gating defect linked to an altered protein
conformation, F508del-CFTR acquires some degree of function
if rescued and stabilized at the PM.12,13 Restoring even less than
30% of CFTR function in vivo is believed to confer an at least
partial clinical benefit to CF patients.14,15 As proof of this con-
cept, rescuing approximately 20% of function of wild-type
CFTR largely prevents the CF-associated intestinal manifesta-
tions in newborn F508del-CFTR homozygous pigs, a species
that, like mice, exhibits a preponderant intestinal phenotype in
CFTR-mutated newborns.16 Although correctors have become
available to improve the maturation and trafficking of the unsta-
ble F508del mutant protein at the PM,6 a CFTR-repairing ther-
apy is not yet clinically available. The investigational F508del
corrector VX-809, which is endowed with a high rescuing effi-
cacy in vitro and in primary cultures of lung cells from CF
patients,17-19 showed only modest efficacy in a phase II clinical
trial in CF patients homozygous for the F508del-CFTR
mutant.17 VX-809 20 and another corrector, VX-661,21 are now
being evaluated in clinical trials in combination with the
potentiator VX-770 for the treatment of homozygous F508del-
CFTR CF patients.22, 23
Besides these mutation-specific approaches, more general ther-
apeutic strategies6 advocating the improvement of proteostasis
have emerged.24,25 Thus, a complex derangement of proteostasis
takes place in human bronchial F508del-CFTR homozygous epi-
thelial cell lines, as well as in the lungs from F508del-Cftr homo-
zygous (CftrF508del) mice.26-28 Dysfunctional F508del-CFTR
protein induces persistent activation of TGM2 (transglutaminase
2),29,30 resulting in cross-linking of several TGM2 substrates,
including BECN1,26 a protein essential for autophagy. This leads
to functional sequestration of the BECN1 interactome in intra-
cellular aggregates, resulting in defective autophagy with conse-
quent accumulation of the autophagic substrate SQSTM1.26
Transgene-enforced BECN1 overexpression, knockdown of
SQSTM1 by means of small interfering RNAs (siRNAs), or addi-
tion of autophagy-stimulatory proteostasis regulators, such as
cystamine, a known TGM2 inhibitor, can reduce the abundance
of inflammatory cytokines both in CFBE41o- bronchial epithe-
lial cells derived from F508del-CFTR homozygous CF patients,
as well as in lungs from CftrF508del mice.26,27 These treatments
can increase the expression level of F508del-CFTR protein and
restore its function at the PM. 26,27 Notably, the positive effects
of cystamine extend for a while beyond its washout unless the
autophagic response is abrogated or CFTR function is inhibited
by the functional CFTR inhibitor 172 (CFTRinh-172) during
cystamine washout. This indicates that prior re-establishment of
autophagy prolongs the persistence at the epithelial surface of a
sufficient amount of functional F508del-CFTR to interrupt, for
a while, the negative loop that compromises its PM residence
and function.31 We have reported that a CFTR-sufficient envi-
ronment is required to allow F508del-CFTR to traffic to and
reside at the PM of bronchial epithelial cells.31 Accordingly,
when F508del-CFTR is transfected into cells, the resulting pro-
tein is not expressed in the PM of CFTR-deficient HeLa cells,
yet is capable of trafficking to and residing at the PM of CFTR-
sufficient normal bronchial epithelial cells, unless these latter cells
are treated with CFTRinh-172.
31 Indeed, the functional inhibi-
tion of CFTR in normal bronchial epithelial cells ignites the
removal of endogenous wild-type CFTR from the PM by divert-
ing CFTR recycling to lysosomal degradation.31 Proteostasis reg-
ulators such as cystamine interrupt this negative feed forward
loop (in which a functional CFTR defect entails the destruction
of PM-sessile CFTR protein) and create a permissive environ-
ment for the restoration of CFTR function.27,31 The ability of
cystamine to rescue and conserve F508del-CFTR in mouse and
human respiratory cells may also enable the beneficial action of
CFTR potentiators.27 These observations highlight cystamine as
a potential candidate drug for the therapy of CF patients harbor-
ing the F508del-CFTR mutation.
Oral administration of cysteamine, the reduced form of cyst-
amine, has been FDA (Food and Drug Administration) approved
for the treatment of cystinosis, a rare genetic disease.32 Morever,
clinical trials suggest the efficacy of cysteamine in children suffer-
ing from nonalcoholic fatty liver disease.33 Driven by the excel-
lent safety profile of cysteamine, we investigated whether the oral
2054 Volume 10 Issue 11Autophagy
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administration of this compound could rescue CFTR function
and improve CF symptoms in vivo. Here we report the therapeu-
tic effect of cysteamine on CftrF508del mice as well as the capacity
of cysteamine to improve CFTR function of ex vivo cultured air-
way epithelia from CF patients carrying the F508del-CFTR
mutation. Encouraged by these preclinical data, we performed a
phase II study revealing an unprecedented clinical efficacy of cys-
teamine in CF patients homozygous for the F508del mutation.
Results
Therapeutic effects of oral cysteamine on CftrF508del mice
In pigs and mice, loss-of-function mutations of Cftr cause a
predominantly intestinal phenotype.16,34-36 Thus 50% to 90%
of cftr KO mice die in the first 4 wk after birth, mostly due to
intestinal obstruction,34 and up to 40% of F508del-Cftr homozy-
gous (CftrF508del) mice die during the same period,37 unless they
are kept under a special diet that reduces the risk of obstruc-
tion.38 We evaluated the hypothesis that oral administration of
cysteamine might avoid the juvenile overmortality of CftrF508del
mice. A total of 297 2-wk-old mice were fed with a normal diet
and randomized to receive cysteamine (n D 159, females 70) or
vehicle (n D 138, females 65), without prior knowledge of their
genotype. Starting from the 15th d of life, mice were treated via
gavage with vehicle alone (100 ml saline solution/day) or cyste-
amine (60 mg/kg in 100 ml saline/day) for 5 wk or until sponta-
neous death, followed by genotyping. Among the control mice,
which were either wild type or heterozygous for the F508del-
CFTR mutation, none died. In contrast, the mortality of
CftrF508del mice (n D 82) was 49% in the vehicle-treated (n D
47) and 9% in the cysteamine-treated (n D 35) groups, respec-
tively. Kaplan-Meier survival plots revealed significant (Log-
Rank test, P D 0.0001) effects of cysteamine with a 2-wk-survival
probability of 60% versus 91% for vehicle-versus cysteamine-
treated groups, respectively (Fig. 1A and 1B; Fig. S1). Immuno-
blots of intestinal lysates of CftrF508del mice revealed that CFTR
protein was significantly increased after cysteamine treatment as
compared to vehicle-treated mice, reaching a mean value of 58%
(range 57% to 65%) of that observed in wild-type control mice
(Fig. 1C and 1D). To assess CFTR function in vivo, the response
of the rectal potential difference (RPD) to the presence of forsko-
lin and luminal amiloride (100 mM, to block NaC-dependent
RPD) in Cl¡ free solutions39 was determined. In wild-type mice,
perfusion with forskolin (20 mM) induced significant RPD
hyperpolarization, indicating activation of Cl¡ conductance in
the rectal epithelium, and this DRPD was not affected by treat-
ment with cysteamine. In contrast, CftrF508del mice failed to dem-
onstrate a DRPD unless they were treated with cysteamine
(Fig. 1E and 1F). These results indicate that cysteamine is able to
induce forskolin activated RPD in CftrF508del mice.
Notably, the oral administration of cysteamine restored BECN1
protein levels in intestinal lysates ofCftrF508delmice to levels compa-
rable to those observed in wild-type mice (Fig. 1C and 1D).
While cysteamine had no effect on the weight gain of control
mice (either WT or heterozygous for the F508del-CFTR
mutation) over the experimental period, cysteamine-treated
CftrF508del mice gained significantly (The Student t test, P <
0.01) more weight than did vehicle control CftrF508del mice
(Fig. 2A and 2B).
Concomitantly, oral administration of cysteamine was also
effective in controlling lung inflammation, as it decreased the
abundance of Tnf and Cxcl2 (chemokine (C-X-C motif) ligand 2)
transcripts in the lungs of young CftrF508del mice (n D 5, the Stu-
dent t test, P < 0.01) (Fig. 2C) enrolled in this 5-wk experiment.
Furthermore, oral administration of cysteamine rescued CFTR
protein in lungs of young CftrF508del mice, and restored BECN1
protein to the levels of wild-type mice (Fig. 2D and 2E).
Gavage of cysteamine for a shorter period (7 d, 100 ml saline
solution) also reduced the expression of Tnf and Cxcl2 mRNAs
(n D 5, the Student t test, P < 0.001) in the lungs of older (10 to
12 wk-old) CftrF508del mice (Fig. S2).
Together, these data indicate that oral administration of cyste-
amine has a major positive effect on the intestinal and respiratory
tracts of CftrF508del mice.
Effects of combination treatment with cysteamine and
epigallocatechin gallate on human airway epithelial cells and
mouse lungs
Driven by the positive outcome of the mouse experiments, we
next investigated the possibility that cysteamine, like cyst-
amine,28,31,40 would rescue F508del-CFTR at the plasma mem-
brane (PM) and sustain the residence of CFTR mutant after
washout in vitro, in polarized CFBE41o- human bronchial epi-
thelial cell lines.27 The cells were transfected with F508del-CFTR
at 37 C, then incubated with cysteamine (250 mM) for 18 h,
which was washed out, followed by 24 to 48 h of culture, accord-
ing to a previously described procedure.27 Surface biotinylation,
followed by purification of biotinylated proteins and immuno-
blot detection of CFTR (to detect its expression at the PM), con-
firmed that a sizeable fraction of CFTR protein resided at the
PM after 24 h of cysteamine washout, as described.27 However,
the amount of PM-resident CFTR protein decreased after 48 h
of washout to »20% of the value observed immediately after cys-
teamine treatment (Fig. 3A; Fig. S3A). These results prompted
us to investigate whether a sequential treatment with natural
compounds, with known safety profile, after cysteamine washout
would be able to prolong the beneficial effects of cysteamine in
conserving F508del-CFTR at the PM after withdrawal. We have
previously shown that the CFTR potentiator genistein can
increase the beneficial effects of cystamine after washout in con-
trolling lung inflammation in CftrF508del mice.27 Genistein is a
member of the well-known class of isoflavones, which are natu-
rally occurring and abundant in soybeans and soy-based foods.
However, the use of genistein in CF therapy is limited due to its
undesirable effects on the immune and endocrine systems.41,42
In an attempt to avoid the decline of rescued PM-resident
F508del-CFTR after cysteamine washout, we tested the effects of
another flavonoid, the green tea-derived epigallocatechin gallate
(EGCG). This choice was dictated by the consideration that
EGCG is authorized as an over-the-counter food additive, with a
known safety profile,43 and that EGCG is already being evaluated
www.landesbioscience.com 2055Autophagy
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in clinical trials in CF patients carrying CFTR splice mutants.44
Therefore, we added EGCG (80 mM) for 48 h to the system
during cysteamine washout. We found that EGCG was able to
maintain the PM residence of rescued F508del-CFTR to »80%
of the value observed immediately after cysteamine treatment
(Fig. 3A). Notably, EGCG alone failed to consistently rescue the
PM localization of F508del-CFTR protein and the simultaneous
treatment of the cells with cysteamine plus EGCG did not yield
a better rescue of the F508del-CFTR protein than did treatment
with cysteamine alone (Fig. S4).
EGCG, similarly to other naturally occurring flavonoids
with known beneficial effects on human health,45 has a wide
range of pharmacological
effects.46,47 EGCG
reportedly inhibits several
kinases,48 among which
protein kinase CSNK2
(casein kinase 2 or protein
kinase CK2).49 The inhi-
bition of CSNK2 has
been reported to prevent
the degradation of CFTR
protein, particularly in
the case of F508del-
CFTR mutant.50 In vitro
experiments confirmed
that EGCG (80 mM),
although not being a spe-
cific CSNK2 inhibitor,
inhibited both the
CSNK2 holoenzyme and
its isolated catalytic subu-
nits, whereas cysteamine
failed to do so (Fig. 3B).
Notably, the capacity of
EGCG to sustain the PM
residence of rescued
F508del-CFTR during
cysteamine washout, was
mimicked by addition of
CX-4945 (5 mM),51 a
highly selective CSNK2
inhibitor51 that has been
tested in oncological
phase I clinical trials 52,53
(Fig. 3C). The positive
effects of both EGCG
and CX-4945 during cys-
teamine washout were lost
if the CFTR inhibitor
172 (CFTRinh-172) was
concomitantly added
(Fig. 3A and 3C). There-
fore, inhibition of
CSNK2 could be at least
one of the mechanisms by
which EGCG prolongs
the effects of cysteamine
beyond its withdrawal.
The ability of EGCG
to prolong the long-term
effects of cysteamine
Figure 1. For figure legend, see page 2057.
2056 Volume 10 Issue 11Autophagy
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adiministration beyond its discontinuation, was confirmed in
vivo in CftrF508del mice. We found that short-term oral adminis-
tration of cysteamine (7 d, 60 mg/kg/day) was effective in signifi-
cantly reducing lung mRNAs coding for Tnf and Cxcl2 and these
anti-inflammatory effects lasted well beyond cysteamine discon-
tinuation. The beneficial effect of cysteamine was lost 30 d after
the treatment, unless EGCG (150 mg/kg in 100 ml saline/day
for 30 d) was administered during this period. Hence, EGCG
extended the efficacy of cysteamine in vivo, significantly reducing
the mRNA expression of Tnf (P < 0.001) and Cxcl2 (P < 0.01,
the Student t test) (Fig. 3D).
Altogether these results support the possibility that the combi-
natory treatment with cysteamine and EGCG might be useful
for the treatment of CF patients homozygous for the F508del-
CFTR mutation.
Effects of cysteamine and EGCG on F508del-CFTR
homozygous CF patients ex vivo
Driven by the positive outcome of the mouse experiments, an
open-label phase II pilot study (EudraCT number #2013-
001258-82 approved by Local Ethics Committee, protocol refer-
ence #85/13) was designed to test the efficacy or the combinatory
treatment with cysteamine and EGCG in 10 Caucasian CF
patients homozygous for the F508del-CFTR mutation (Table 1
and 2). These patients were in regular follow-up at the Depart-
ment of Pediatrics, Regional Cystic Fibrosis Care Center, Uni-
versity of Naples Federico II, and were consecutively enrolled
according to the eligibility criteria (Table 2).
Before treatment started, all patients enrolled in the study
underwent nasal brushing, following an established procedure.27
We assessed CFTR channel function by measuring the rate of
iodide efflux in freshly isolated brushed nasal epithelial cells
through a fluorescence-based SPQ assay, to avoid any experimen-
tal manipulation of primary epithelial cells.27 The rate of iodide
efflux was reduced to a mean of 8.6% (range 6.2 to 12.8; SD
1.9) considering the values obtained from 5 non-CF healthy vol-
unteers as 100% control value (Table 3; Fig. 4A; Fig. S5).
Brushed nasal epithelial cells belonging to all 10 CF patients
were also incubated ex vivo for 18 h with 250 mM cysteamine
and then kept in medium for 24 h to 48 h in the presence or
absence of 80 mM EGCG. Incubation of these primary CF cells
ex vivo for 18 h with 250 mM cysteamine27,31 was effective in
rescuing CFTR function to mean levels of 74.4% (range 52.9 to
79.2%, SD 7.9) of the control value (Fig. 4A; Fig. S5). Twenty-
four and 48 h after washout of cysteamine, this value dropped to
63.6% (range 48.6 to 72.3, SD 7.4) and 10.7% (range 7.9 to
13.2, SD 1.73), respectively. The addition of EGCG post cyste-
amine washout sustained (ANOVA, P < 0.001) the function of
CFTR ex vivo, which amounted to 61% (range 47.5 to 68.9, SD
7.0) at 48 h (Fig. 4A; Fig. S5). Notably, these effects of EGCG
were recapitulated by the specific CSNK2 inhibitor CX-4945
(Fig. 4B).
These functional tests could be backed up by measurements of
the abundance of the PM-sessile CFTR protein levels in nasal
epithelial cells from 3 patients (No. 5, 6 and 10). Surface biotiny-
lation and membrane fractionation revealed that the surface-
expressed CFTR was reduced to 17.8% (range 15.1 to 18.3) of
the control values from healthy controls (100%) at baseline, yet
could be increased by short-term (18 h) culture in the presence
of cysteamine to >80% of the control value. EGCG fully
avoided the degradation of the F508del-CFTR protein upon cys-
teamine washout (Fig. 4C and 4D; Fig. S6).
Primary nasal epithelial cells from the 3 CF patients exhibited
low BECN1 protein levels together with a 2.5-fold increase of
the autophagic substrate SQSTM1 in the insoluble protein frac-
tion, as compared to controls (Fig. 5A to C), indicating an inter-
ruption in autophagic flux.26 The incubation with cysteamine
restored BECN1 protein, decreased SQSTM1 down to normal
levels (Fig. 5A to C) and reduced the activation of TGM2, a key
pathogenic player of autophagy inhibition in CF epithelia
(Fig. S7).26 These effects were largely lost after 48 h of cyste-
amine withdrawal, unless EGCG was added to the system
(Fig. 5A to C). It should be noted that EGCG did not exert any
potentiator activity (Fig. S8A). Furthermore, EGCG alone failed
to consistently rescue F508del-CFTR function and the simulta-
neous treatment ex vivo with cysteamine plus EGCG did not
increase F508del-CFTR function as compared to cysteamine
alone (Fig. S8B and S8C).
Together, these results indicate that the sequential treatment
of primary respiratory epithelial cells with cysteamine followed
by EGCG improves the expression and function of the F508del-
CFTR protein.
Figure 1 (See previous page). Effects of 5-wk oral administration of cysteamine on the intestine of 2 wk-old CftrF508del mice. (A) Schematic representa-
tion of the effects of oral administration of cysteamine on the mortality of control (wild-type [WT] homozygotes or WT and F508del heterozygotes) and
CftrF508del mice. (B) Cumulative survival rate in CftrF508del mice (n D 82) orally administered with either vehicle (n D 47) or cysteamine (n D 35) for 5 wk.
Log-rank test, P D 0.0001. (C and D) Effects of cysteamine on CFTR and BECN1 protein levels in the intestine. (C) Mean changes of protein levels in 5
wild-type and 5 CftrF508del mice treated with either vehicle or cysteamine for 5 wk. Mean § SD of 3 independent measurements; **P < 0.01 versus vehi-
cle-treated CftrF508del mice (ANOVA). (D) Top, representative immunoblot with anti-CFTR (Abcam clone CF3) and BECN1 (Abcam clone Ab55878) in 1
mouse per treatment group. Bottom, densitometric measurement in the CftrF508del mouse, as percentage of vehicle-treated WT mouse normalized to
TUBA levels. Mean § SD of triplicates of independent experiments, **P < 0.01 versus vehicle-treated CftrF508del mice (ANOVA). (E and F) Effects of cyste-
amine on rectal potential difference (RPD) in response to 20 mM forskolin (Fsk) in 5 WT and 5 CftrF508del mice treated with vehicle or cysteamine. Measure-
ments were conducted during continous perfusion with a Cl¡ free solution containing 100 mM amiloride. (E) Mean changes of RPD (DRPD) in response to
Fsk in 5 WT and 5 surviving CftrF508del mice. Responses in CftrF508del mice were significantly smaller than in wild-type mice; responses in cysteamine-
treated CftrF508del mice were significantly higher than in vehicle-treated CftrF508del mice. Mean § SD of 5 measurements in each group; ###P < 0.001 ver-
sus vehicle-treated WT mice;  P< 0.05 versus vehicle-treated CftrF508del mice (ANOVA). (F) Representative response to Fsk (arrow) in one WT and one sur-
viving CftrF508del mouse per treatment group.
www.landesbioscience.com 2057Autophagy
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 D
un
de
e] 
at 
08
:37
 27
 Ja
nu
ary
 20
16
 
Effects of oral combination treatment on CF patients in vivo
In the next step, patients (mean age 15.6 y, range 8.6 to 25.0,
6 F) received cysteamine bitartrate (trade name Cystagon,
Orphan Europe) at the same doses recommended for patients
with cystinosis (FDA number NDA020392), and epigallocate-
chin gallate (EGCG) (trade name Epinerve, SIFI Pharmaceuti-
cals). Both drugs were orally administered. Cystagon (150 to
300 mg of cysteamine base every 6 h, based on the short half-life
Figure 2. Effects of 5-wk oral
administration of cysteamine
on weight gain and lung
inflammation in 2 wk-old
CftrF508del mice. (A and B)
Effects of cysteamine on
weight gain. (A) Distribution
of weight (g) variation of
CftrF508del mice (n D 56)
orally treated with either
vehicle (n D 24) or cyste-
amine (n D 32) for 5 wk;
P < 0.01 (Student t test).
(B) Representative picture
showing difference in body
size at the end of treatment
in one vehicle-treated (left)
and one surviving
cysteamine-treated (right)
CftrF508del mice. Scale bar:
1 cm. (C) Effects of cyste-
amine on Tnf (left) and Cxcl2
(right) transcription levels in
lung homogenates from 7-
wk-old CftrF508del mice
treated with either vehicle or
cysteamine. Mean § SD of
triplicates of 5 surviving
mice per group;
P < 0.01 (The Student t
test). (D to E) Effects of cyste-
amine on CFTR, and BECN1
protein levels in the lungs.
(D) Mean changes of protein
levels in 5 wild-type and 5
CftrF508del mice treated with
either vehicle or cysteamine
for 5 wk. Mean § SD of 3
independent measurements;
**P < 0.01 versus vehicle-
treated CftrF508del mice
(ANOVA). (E) Top, representa-
tive immunoblot with anti-
CFTR (Abcam clone) and
anti-BECN1 (Abcam clone
Ab55878) in one mouse per
treatment group. Bottom,
densitometric measurement
in the CftrF508del mouse, as
percentage of vehicle-
treated WT mouse normal-
ized to TUBA/a-b tubulin
levels. Mean § SD of tripli-
cates of independent experi-
ments, **P < 0.01 versus
vehicle-treated CftrF508del
mice (ANOVA).
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of the agent, Fig. S9A
and S9B) was given
alone for 4 wk, followed
by a combination of Cys-
tagon (same dose) with
Epinerve (270 mg once
daily) for a further 4 wk,
followed by Epinerve
(270 mg once daily) only
for the final 4-wk period
of this 3-mo treatment
(Table 2). The pharmaco-
kinetic profile of Cys-
tagon in patients
homozygous for the
F508del-CFTR mutation
recapitulates that observed
in patients with cystinosis
(Fig. S9A and S9B).
During treatment,
the patients remained on
their prestudy stable
medication, including
inhaled antibiotics.
Patients were followed
up for a further 8 wk
beyond the end of treat-
ment (Table 2). Minor
adverse events were regis-
tered as single episodes
in different patients
within a few days after
treatment started. These
side effects include mild
upper abdominal pain
(7 patients), nausea
(6 patients), halithosis (5
patients) and altered
smell of the skin (2
patients). All of the
patients complied with
the medication until the
end of the study. As pri-
mary endpoints, we
determined CFTR func-
tion using 2 assays,
namely, (i) the rate of
iodide efflux27 in freshly
isolated brushed nasal
epithelial cells from the
enrolled patients com-
pared to 5 adult non-CF
healthy volunteers, and
(ii) sweat chloride levels.
As secondary endpoints,
we monitored sputum
Figure 3. For figure legend, see page 2060.
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and nasal levels of the inflammatory cytokines TNF and CXCL8,
and we performed spirometry to determine the forced expiratory
volume of the first second (FEV1) and the mid-flow rate of forced
expiratory flow occurring between 25% and 75% of the patient’s
exhaled volume (FEF25-75%), both of which were expressed as
percentage of the predicted normal value. All clinical and labora-
tory parameters were assessed at baseline (wk 0) and after 4, 8
and 12 wk of treatment. Spirometric tests and sweat chloride
measurements were also performed 4 and 8 wk after the cessation
of experimental medication (wk 16 and 20) (Table 2).
Effects of in vivo treatment on chloride function in nasal
epithelial cells
The rate of iodide efflux from freshly isolated brushed nasal epi-
thelial cells increased throughout the study in all patients (Fig. 6A;
Fig. S10). The percentage of rescued CFTR function augmented
from mean 8.6% (range 6.2 to 12.8, SD 1.9) at wk 0 to 18.2%
(range 8.8 to 29.2, SD 8.4), 28.2% (range 14.6 to 54.0, SD 10.5)
and 24.6% (range 15.1 to 33.2, SD 6.9) of the values of non-CF
healthy controls (considered as 100% of function) after 4, 8 and 12
wk of treatment, respectively (P D 0.0003 at wk 8, P D 0.0002 at
wk 12, as compared to pretreatment values, ANOVA) (Fig. 6A).
The reestablishment of CFTR function was confirmed by
immunoblot analyses of nasal epithelia from 3 patients (No. 5, 6,
10). The abundance of CFTR band C raised from mean 9.1%
(range 8.4 to 10.9) (considering healthy controls as 100% reference
value) pretreatment to 52.8% (44.9 to 66.0) and 31.3% (9.1 to
45.0) after 8 and 12 wk of treatment, respectively (Fig. 6B to 6D;
Fig. S11). Concomitantly, the protein BECN1 increased from
mean 23.0% (range 20.7 to 25.8; 100% equals the value of healthy
controls) before treatment to 47.3% (range 39.6 to 56) and 45.0%
(range 40.8 to 50.0) after 8 and 12 wk (Fig. 7A and 7B), and
SQSTM1 protein decreased from supranormal values before treat-
ment (»250% of control values) to close-to-normal values after 8
and 12 wk of treatment (Fig. 7A and 7C). These data indicate that
the in vivo treatment effectively rescued the expression and function
of respiratory epithelial CFTR protein, as it normalized autophagy-
related parameters in CF patients.
Effects of in vivo treatment on sweat chloride levels
Before treatment (wk 0), all patients exhibited sweat chloride
concentrations >60 mMol (mean 94.1, range 67 to 153). As a
result of the treatment, sweat chloride levels decreased <60
mMol in 7 patients (No. 1, 2, 5, 6, 7, 8 and 10 of Table 1), who
were all under 18 y, corresponding to a decrease by >30% (range
32.3 to 75.8) of the baseline value, and these positive effects
Table 1. Baseline Characteristics of the Patients
Sex Age (years) Weight (Kg) Height (cm) BMI PA
FEV1 %
predicted
FEF25-75 %
predicted
Sweat chloride
(mmol/liter)
1 M 15.8 58.2 160.0 22.73 ¡ 103.6 50.0 71
2 M 10.7 37.3 131.0 21.70 ¡ 75.7 39.0 88
3 F 19.8 46.2 159.0 18.27 ¡ 81.3 28.1 76
4 F 25.0 53.0 160.3 20.62 ¡ 74.6 29.4 84
5 M 13.6 45.8 156.0 18.82 ¡ 95.9 53.1 115
6 F 17.7 44.1 151.0 19.34 C 89.6 52.7 113
7 F 12.0 44.6 146.5 20.80 ¡ 113.1 105.9 67
8 F 15.6 52.5 161.3 20.18 C 109.3 62.6 100
9 F 17.8 48.0 153.5 20.37 C 77.8 24.5 74
10 M 8.6 32.6 132.5 18.57 ¡ 101.2 42.9 153
PA, Pseudomonas aeruginosa.
Figure 3 (See previous page). Effects of the combination treatment with cysteamine and epigallocatechin gallate (EGCG) on human airway epithelial
cells and mouse lungs. (A) CFBE41o-cells were transfected with F508del-CFTR at 37 C. After transfection, the cells were incubated for 18 h with or with-
out cysteamine (250 mM) and then kept in medium for 24 h or 48 h in the presence or absence of EGCG (80 mM), with or without CFTRinh-172 (20 mM).
Cycloheximide (CHX) (100 mg ml¡1) was added during the last 8 h of incubation. The lack of CHX toxicity in this model is reported in Fig. S3A. Top, sur-
face biotinylation followed by purification of streptavidin-bound PM proteins and immunoblot with anti-CFTR (clone CF3, Abcam). FLOT1 (clone C-2
Santa Cruz Biotechnology) confirmed cell surface protein-specific localization. Bottom, densitometric measurement of the residual CFTR at the PM
expressed as fold increase of the initial amount (medium) normalized to FLOT1 levels, Mean § SD of triplicates of independent experiments; P < 0.01
compared to medium (ANOVA). (B) Effects of EGCG (top) and cysteamine (bottom) on the activity of either the CSNK2A/a subunit or the CSNK2A2-
CSNK2B2 (a2b2) holoenzyme acting on the synthetic peptide substrate RRRADDSDDDDD. IC50 values represent the mean of 3 independent experiments
with the SD not exceeding 10%. (C) CFBE41o-cells were transfected with F508del-CFTR and incubated with cysteamine and then kept up to 48 h in
medium alone as in (A). During cysteamine washout, the cells were incubated with medium or medium added with the CSNK2 inhibitor CX-4945 (5 mM)
in the presence or absence of CFTRinh-172 (20 mM). CHX was added to the system as in (A). Top, surface biotinylation followed by purification of streptavi-
din-bound PM proteins and immunoblot with anti-CFTR (clone CF3, Abcam). FLOT1 (clone C-2 Santa Cruz Biotechnology) confirmed cell surface protein-
specific localization. Bottom, densitometric measurement of the residual CFTR at the PM expressed as fold increase of the initial amount (medium) nor-
malized to FLOT1 levels. Mean § SD of triplicates of independent experiments, P < 0.05, P < 0.01 compared to medium (ANOVA). (D) Tnf (top) and
Cxcl2 (bottom) transcription levels in lung homogenates from 10-12 wk-old CftrF508del mice either immediately after treatment with vehicle or cysteamine
for 7 d or alternatively after a latency of 10, 20, or 30 d without cysteamine treatment. During this “washout” period, the mice were either left untreated
or treated with cysteamine. Mean § SD of triplicates of 5 mice per group, P < 0.05, P < 0.001 compared to vehicle and **P < 0.01, ***P < 0.001 com-
pared to 30 d of washout without cysteamine (ANOVA).
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lasted beyond the cessation of the treatment. In 2 out of the
remaining 3 patients (No. 4 and 9 of Table 1) sweat chloride lev-
els decreased to <60 mmol per liter (54 and 47 mmol per liter,
corresponding to »36% decrease with respect to the level before
treatement) beyond discontinuation of the pharmacological treat-
ment (wk 16 or wk 20) (Fig. 8A; Fig. S12; Table 3). The
decrease in sweat chloride was significant after 12 wk of treat-
ment (P D 0.0029, ANOVA) (Fig. 8A; Table 3), and correlated
with the amelioration. The decrease in sweat chloride correlated
with the amelioration of CFTR function measured in nasal epi-
thelia after 8 wk of treatment (The Spearman r D ¡0.883, P D
0.001) (Fig. 8B).
Effects of in vivo treatment on respiratory inflammation
A significant reduction of mRNA levels of TNF and CXCL8
was observed in brushed nasal epithelial cells after 12 wk of treat-
ment (P D 0.026 and P D 0.023 vs baseline values, respectively)
(Fig. 9A and 9B). The levels of the inflammatory cytokines in
the sputum also significantly decreased during the treatment, as
true for both TNF (8 wk: P D 0.0019; 12 wk: P D 0.016) and
CXCL8 (8 wk: P D 0.024) (Fig. 9C and 9D). The absolute
change from baseline values in TNF protein levels in the sputum
after 12 wk of treatment significantly correlated with the decrease
of sweat chloride levels early during treatment (The Spearman
r D 0.770, P D 0.009) (Fig. 9E). Altogether, these results indi-
cate that all laboratory parameters investigated in this study
improved after treatment with cysteamine plus EGCG.
In addition, although the spirometric values (FEV1 and
FEF25-75%) failed to reach a significant increase over the observa-
tion period, the average changes in FEV1 and FEF25-75% were
5.1% (range -14.3; 35.9) and 3.8% (range -6.6; 36.7), respec-
tively, at the end of treatment (wk 12), and tended to increase
(mean 5.4% (range -13.1; 43.0) and 10.9% (range -6.9; 64.4)
during the observation period after discontinuation of the treat-
ment (wk 16) (Fig. S13; Table 3).
Discussion
CFTR repairing strategies are an emerging option in CF ther-
apy.54 Rescuing a functional F508del-CFTR mutant at the PM
Table 2. Study design
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of epithelial cells is the focus of a series of drug discovery pro-
grams. This strategy is usually based on a protein-specific
approach by means of small molecules (pharmacological chaper-
ones) that would ideally either promote protein folding and cor-
rect the mislocalization of the mutant protein (CFTR correctors)
or increase the defective CFTR chloride channel function
(CFTR potentiators).6,7,55 In addition, an increasing number of
small organic molecules can mimic the activity of pharmacologi-
cal chaperones by modulating the folding machinery or protein
stability (chemical chaperones).56 Besides these approaches that
target the F508del-CFTR protein, alternative approaches aim at
modulating CFTR interacting proteins, such as intracellular
chaperones, or generally target the proteostasis network.6
Recently, we have demonstrated that restoring disabled
autophagy is a new strategy to circumvent CFTR defect. We dis-
covered that cystamine, a small molecule that acts as a modulator
of proteostasis, is able to rescue and stabilize F508del-CFTR at
the PM of CFBE41o- airway epithelial cell lines as well as in pri-
mary human nasal epithelial cells.27,28,31 In this study we evalu-
ated the therapeutic potential of cysteamine, the reduced form of
cystamine, stimulated by the fact that cysteamine is an FDA-
approved drug with a known safety profile and good bioavailabil-
ity upon oral administration.57 In a preclinical animal model, the
CftrF508del mouse, we observed that the oral treatment for 5 wk
with cysteamine significantly reduced mortality, improved weight
gain, and increased the expression of functional CFTR protein at
the intestinal level, at the same time that it restored BECN1 pro-
tein expression to wild-type levels.
Table 3. Treatment Effects
Core study measures Visit (V) Patients
1 2 3 4 5 6 7 8 9 10
Sweat test
Cl¡ (mmol/l) V1 71 88 76 84 115 113 67 100 74 153
V2 72 90 80 70 95 79 61 97 82 89
V3 52 76 64 74 74 51 52 104 69 37
V4 48 42 63 76 58 55 45 51 87 93
V5 57 70 70 66 65 53 58 61 47 87
V6 93 96 104 54 95 102 71 104 92 83
Nasal brushing
I¡ efflux % control V1 7.3 8.3 7.1 7.6 8.9 6.2 7.1 10.2 12.8 10.2
V2 9.2 18.6 8.8 29.7 28.7 20.4 10.0 13.4 14.1 29.2
V3 20.5 25.9 27.1 31.0 29.5 31.6 27.6 14.6 20.3 54.0
V4 16.5 29.6 28.5 29.0 28.7 30.0 33.2 18.2 15.1 17.0
Sputum
TNF (pg/ml) V1 137.8 174.4 159.5 167.2 461.8 111.5 152.3 345.7 93.2 517.9
V2 292.6 27.3 254.3 38.4 34.1 69.0 137.4 30.2 216.1 4.3
V3 3.9 6.7 43.5 71.9 5.6 0.1 2.2 43.5 23.9 24.6
V4 1.4 160.8 224.6 0 66.0 1.8 6.0 18.8 140.5 121.3
CXCL8 (pg/ml) V1 1576.9 43.8 429.4 298.7 77.9 74.0 911.7 548.5 156.3 1431.7
V2 1386.2 198.9 1153.7 37.2 0 15.9 6.2 0 2649.9 0
V3 0 0 54.7 232.8 0 0 0 69.2 130.2 48.8
V4 0 1820.9 1303.8 0 0 0 0 180.5 650.2 0
Respiratory function
FEV1 liters V1 3.04 1.28 2.48 2.34 2.66 2.13 2.45 3.04 1.91 1.71
V2 2.84 1.65 2.74 2.26 2.74 2.14 2.45 2.90 2.01 1.60
V3 3.17 1.73 2.54 2.20 2.99 2.38 2.62 2.65 1.91 1.54
V4 2.94 1.75 2.89 2.43 2.67 2.40 2.46 2.90 2.05 1.60
V5 3.61 2.00 2.66 2.47 2.93 2.18 2.56 3.22 1.87 1.62
FEV1 % V1 103.6 75.7 81.3 74.6 95.9 89.6 113.1 109.3 77.8 101.2
V2 96.9 97.9 89.7 72.1 98.6 90.2 113.1 104.2 81.8 94.6
V3 108.3 102.4 83.2 70.0 107.7 100.1 116.7 93.6 78.0 87.7
V4 100.3 103.5 117.2 77.7 91.2 101.1 109.2 102.5 83.5 86.9
V5 120.8 118.7 87.1 78.7 98.1 91.7 113.8 113.9 66.5 88.1
FEF25-75 liters/sec V1 1.71 0.85 1.14 1.20 1.74 1.60 2.96 2.17 0.77 0.93
V2 1.58 1.46 1.56 1.26 1.63 1.22 3.01 2.24 0.90 0.77
V3 1.73 1.30 1.58 0.88 2.49 1.76 3.72 1.73 0.76 1.36
V4 1.71 1.65 1.59 0.86 1.59 1.83 2.94 2.18 0.98 0.89
V5 2.48 2.25 1.48 0.91 2.21 1.71 3.25 2.63 0.89 0.79
FEF25-75 % V1 50.0 39.0 28.1 29.4 53.1 52.7 105.9 62.6 24.5 42.9
V2 46.2 67.0 38.5 31.0 49.7 40.2 107.6 64.9 28.9 35.6
V3 50.5 60.0 39.0 21.6 76.2 58.2 128.7 49.0 24.2 60.5
V4 50.0 75.7 39.2 21.0 46.5 60.5 101.8 62.0 31.2 38.3
V5 71.4 103.4 36.5 22.3 63.8 56.5 112.4 74.6 22.3 33.9
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Ideally, compounds used for lifetime ther-
apy should be endowed with the ability to
mediate long-term benefits after short-
term pulses of treatment to avoid undesir-
able effects. The effects of cysteamine in reducing respiratory
inflammation extend for a short period beyond its withdrawal and
rely on the cell’s ability to conserve a functional F508del-CFTR at
the PM and to restore autophagy, as they are abrogated if autoph-
agy is inhibited by 3-methyladenine or if CFTR function is
inhibited by CFTRinh-172 during the washout period.
27,31 There-
fore, the identification of natural compounds with known safety
profile, capable of prolonging the beneficial effects of cysteamine
after withdrawal, could be of great value in CF therapy. Here we
show that the effects of cysteamine after withdrawal can be further
Figure 4. Effects of cysteamine and EGCG on
surface CFTR in ex vivo cultured primary
human nasal epithelial cells belonging to the
enrolled F508del-CFTR homozygous CF
patients. Freshly isolated brushed nasal epi-
thelial cells were collected from 10 F508del-
CFTR homozygous patients and cultured for
18 h with or without cysteamine (250 mM)
and then kept for 24 or 48 h in medium or
medium added with EGCG (80 mM). Brushed
nasal epithelial cells from 5 non-CF healthy
controls were cultured with medium alone.
(A) Assessment of iodide efflux by a fluores-
cence assay (SPQ) upon stimulation with for-
skolin (Fsk) plus 3-Isobutyl-1-methylxanthine
(IBMX). Rate of iodide efflux, expressed as
percentage of values of 5 healthy controls.
The analysis was performed on at least 50
cells per sample and per experiment. Mean
§ SD of 3 experiments for each sample. P
< 0.001 (ANOVA). (B) Effect of incubation
with CX-4549, instead of EGCG, during cyste-
amine washout. Assessment of iodide efflux.
Mean § SD of 3 experiments for each sam-
ple. P < 0.01 (ANOVA). (C and D) Effects of
ex vivo treatment on CFTR protein levels at
the PM of nasal epithelial cells. (C) Mean val-
ues of residual CFTR protein at the PM of
patients No. 5, 6, and 10 of Table 1. The val-
ues are expressed as percentage of non-CF
healthy control (considered as 100% of
value). Mean values of 3 independent experi-
ments for each sample; P< 0.01 compared
to untreated, ##P < 0.01 compared to non-
CF healthy control (ANOVA). (D) Left, repre-
sentative blot of CFTR protein levels at the
PM of nasal epithelial cells from one out of 5
non-CF control and one patient (No. 10 of
Table 1) out of 3 patients analyzed. Right,
representative blot of CFTR protein levels at
the PM of nasal epithelial cells from patient
No. 10 cultured ex vivo as indicated. Top, sur-
face biotinylation followed by purification of
streptavidin-bound PM proteins and immu-
noblot with anti-CFTR (clone CF3, Abcam).
FLOT1 confirmed cell surface protein-specific
localization. Bottom, densitometric measure-
ment of the residual CFTR at the PM
expressed as percentage of non-CF healthy
control (100% of value) normalized to FLOT1
levels. Mean § SD of triplicates of indepen-
dent experiments; P < 0.01 compared to
untreated, ##P < 0.01 compared to non-CF
healthy control (ANOVA).
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sustained by the addition of a natural compound, the green tea-
derived flavonoid epigallocatechin gallate.58 Although not effective
on its own in rescuing mutant CFTR protein, EGCG can help
conserving F508del-CFTR rescued at the PM when added during
the period in which cysteamine was removed from the system.
EGCG is a multifunctional compound
that can exert beneficial effects on
human health by modulating a panel of
intracellular pathways.43,45,46 Here we
selected EGCG on the basis of its ability
to modulate the activity of one particular
Ser/Thr kinase, CSNK2, a “master pro-
tein kinase” involved in multiple cellular
processes.59 CSNK2 activity is reportedly
involved in the proteolytic degradation
of F508del-CFTR50,60 in a self-sup-
ported loop where CSNK2 ultimately
promotes fragmentation/degradation of
CFTR such that the resulting CFTR
fragments allosterically activate
CSNK2.61 Thus, targeting CSNK2
could represent an alternative approach
to improve F508del-CFTR stability, in
accord with the finding that a highly
selective inhibitor of CSNK2 mimicked the capacity of EGCG to
sustain F508del-CFTR function beyond cysteamine washout.50,60
Notably, the ex vivo treatment of nasal epithelial cells with
EGCG during cysteamine washout, stabilized the protein levels
of BECN1 and SQSTM1. Disabled autophagy correlating with
Figure 5. Effects of cysteamine and EGCG
on BECN1 and SQSTM1 protein levels in ex
vivo cultured primary human nasal epithe-
lial cells belonging to the enrolled F508del-
CFTR homozygous CF patients. (A and B)
Effects of ex vivo treatment on BECN1 and
SQSTM1 protein levels in nasal epithelial
cells. (A) Mean values of BECN1 and
SQSTM1 of patients No. 5, 6 and 10 of
Table 1. The values are expressed as per-
centage of non-CF healthy control (consid-
ered as 100% of value). Mean values of 3
independent experiments for each sample;
P < 0.01 compared to untreated, ##P <
0.01 compared to non-CF healthy control
(ANOVA). (B and C) Representative blot of
BECN1 and SQSTM1 protein levels in nasal
epithelial cells from (B) one out of 5 non-
CF control and one patient (No. 10 of
Table 1) out of 3 patients analyzed and (C)
patient No. 10 cultured ex vivo, as indi-
cated. Top, western blot analysis of insolu-
ble and soluble protein fractions and
immunoblot with anti-BECN1 (Abcam) and
anti-SQSTM1 (Sigma Aldrich). ACTB was
used as negative marker of the insoluble
protein fraction and as loading control of
the experiment. Bottom, densitometric
measurement of BECN1 in the soluble frac-
tion and SQSTM1 level in the insoluble pro-
tein fraction expressed as percentage of
non-CF healthy control. Mean § SD of trip-
licates of independent experiments; P <
0.01 compared to untreated, ##P < 0.01
compared to non-CF healthy control
(ANOVA).
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the sequestration of BECN1 interactome ultimately results in
reduced availability of PtdIns3-phosphate at the early endosomes,
thereby impairing CFTR recycling at PM and resulting in its
degradation.26,27,31 Moreover, accumulating SQSTM1 can bind
ubiquitinated CFTR through its ubiquitin-binding domain, thus
targeting PM CFTR to lysosomal degradation.27,31 Maintaining
appropriate autophagic flux therefore could help conserving a
sufficient amount of rescued F508del-CFTR at the PM to inter-
rupt the feed forward loop
that ignites CFTR
disposal.
We predicted the
effects of combined treat-
ment ex vivo in freshly iso-
lated primary nasal
epithelial cells collected
from the patients enrolled
in the study before in vivo
therapy. Primary respira-
tory cell cultures derived
from CF patients are con-
sidered the gold standard
to validate compound effi-
cacy27,62 and might help
as an ex vivo test to predict
the propensity of each
individual patient to bene-
fit from the in vivo admin-
istration of the candidate
drug. We observed that
cysteamine could rescue
>70% of the expression of
functional CFTR mutant
in ex vivo cultures of
freshly isolated patients’
nasal epithelial cells. To
our knowledge, the combi-
nation of 3 different clas-
ses of correctors previously
restored in vitro mutant
CFTR protein level only
to 40% to 50% of the con-
trol levels observed in
healthy subjects bearing
wild-type CFTR.63
Encouraged by these
preclinical results, we per-
formed a phase II open-
label pilot clinical trial in
10 CF patients homozy-
gous for the F508del-
CFTR mutant. Our data
revealed that the oral
administration of the com-
bination therapy was effec-
tive in rescuing iodide
efflux in nasal epithelia to up to 28% of the wild-type values, cor-
relating with an increase in the expression level of the F508del-
CFTR protein. Thus, rescuing >70% of functional F508del-
CFTR in vitro in primary respiratory cells collected before in
vivo treatment started, might predict a significant (>25%) thera-
peutic effect in vivo.
The combination therapy was effective in significantly reduc-
ing sweat chloride levels, a well-representative surrogate marker64
Figure 6. For figure legend, see page 2066.
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of CFTR function. Sweat chloride levels fell below 60 mmol per
liter in 9 out of 10 patients, either during treatment (which was
the case for 7 patients) or shortly thereafter (which was the case
in 2 patients). Importantly, the reduction in sweat chloride con-
centrations correlated with the improvement of iodide efflux
measured in nasal epithelial cells.
Our previous preclinical data indicated that cystamine con-
trolled both signs of inflammation and hyper-responsiveness to
lipopolysaccharide from Pseudomonas aeruginosa in CF mice
through restoration of autophagy.27 Accordingly, it has been
reported that restoring autophagy can mediate bacterial clearance
and depleting SQSTM1 can improve the delivery of bacteria to
the autophagic machinery, ultimately favoring their clearance
from CF macrophages.65,66 The anti-inflammatory effects of cys-
teamine lasted for one wk beyond its removal from the experi-
mental system.27 Notably, these effects were not due to putative
intrinsic antiinflammatory properties of cystamine and rather
relied on the ability of cystamine to sustain CFTR function,
because the functional inhibition of CFTR abrogated the antiin-
flammatory effects of cystamine during washout.27,31 Here, we
show that cysteamine, alone and then combined with EGCG,
reduced signs of inflammation, both in lungs, as revealed by the
decrease of TNF and CXCL8 in the sputum, and in nasal epithe-
lia. A significant correlation between early reductions in sweat
chloride and later (wk 12) improvements in inflammatory
parameters in the sputum supports the notion that the antiin-
flammatory effects of the treatment are secondary to the normali-
zation of CFTR function.
Our data demonstrate that the combination therapy reverted
the key pathogenic mechanisms causing mismanaged proteostasis
in CF epithelia.26,27,31 Indeed, the in vivo treatment increased
BECN1 protein and reduced SQSTM1 levels to the values of
non-CF controls. Since restoration of BECN1 and autophagy
with reduction of SQSTM1 accumulation are key events in sus-
taining the residence of CFTR at the PM of respiratory epithelial
cells,26,27,31 our data suggest that re-establishment of autophagy
could be a predictive marker of efficacy of CFTR-repairing
strategies.
Our pilot trial enrolled a small number of patients without the
inclusion of placebo-treated control groups. Moreover, our trial
was too short to measure possible significant effects on lung func-
tion. Given these limitations, these data must be confirmed in
larger clinical trials. Prompted by the encouraging results
obtained in this first pilot trial, we are now in the process of
launching a new long-term trial that will enroll a much larger
cohort of patients, as well as adequate control groups.
Materials and Methods
Human subjects
Study design. Ten patients with CF, homozygous for F508del-
CFTR mutation, were consecutively enrolled for an open-label
phase II pilot study (EudraCT number #2013-001258-82
approved by Local Ethics Committee, Protocol reference #85/
13) at the Department of Pediatrics, Regional Cystic Fibrosis
Care Center, University of Naples Federico II. The patients and
their parents provided written informed consent. Clinical charac-
teristics of patients, study design and inclusion criteria are
reported in Table 1 and Table 2.
Exclusion criteria were as follows: i) treatment with glucocor-
ticoids per os or via inhalation at screening or within 4 wk before
screening visit; ii) treatment with oxygen or with other experi-
mental drugs; iii) referred hypersensitivity (local or general) to
cysteamine or penicillamine prior study; iv) modifications of
therapeutic regimens in patients assuming macrolides, antiasth-
matic, mucolytic drugs, Dornase alfa, and/or FANS, within 28 d
before screening visit; v) organ transplantation; vi) kidney or
hepatic alterations at screening visit: vii) pregnancy or nursing at
screening visit; viii) refusing to employ contraceptive methods
during the study; ix) psychiatric pathologies or neurological
diseases.
Spirometry was performed in all CF patients according to
American Thoracic Society guidelines.67 Sweat chloride values
were obtained by quantitative pilocarpine iontophoresis accord-
ing to the standardized protocol of Gibson and Cooke.68
Five adult non-CF healthy volunteers underwent nasal brush-
ing at each time at which nasal epithelial cells were collected by
nasal brushing from CF patients (wk 0, 4, 8, 12) and used as con-
trol for the iodide efflux and biochemical studies in nasal epithe-
lial cells. These subjects provided written informed consent.
Pharmacokinetic and pharmacodynamic analyses
The methodologies of the analyses for plasma cysteamine lev-
els were performed69 as described in Supplemental Materials.
Figure 6 (See previous page). Effects of treatment on CFTR function and sweat chloride levels in vivo in F508del-CFTR homozygous patients. (A) Assessment of
iodide efflux by a fluorescence assay (SPQ) upon stimulation with Fsk plus IBMX. Rate of iodide efflux in freshly isolated brushed nasal epithelial cells collected
from all 10 F508del-CFTR homozygous patients before treatment (wk 0) and after 4, 8 and 12 wk of treatment. Values are expressed as percentage of 5 non-CF
healthy controls at each time point (wk 0, 4, 8 and 12). Red markers indicate mean values. Dashed line indicates 20% of rescued function. The analysis was per-
formed on at least 50 cells per sample and per experiment at each time point. Mean§ SD of 3 experiments for each sample, #PD 0.0003 and ##PD 0.0002 versus
wk 0. (B and C) Effects of treatment on CFTR protein levels in freshly isolated nasal epithelial cells. (B) Mean values of CFTR Band C in patients No. 5, 6 and 10 of
Table 1. The values are expressed as percentage of non-CF healthy control (considered as 100% of value). Mean§ SD of triplicates of independent experiments
per each patient’s sample; ##P < 0.01 compared to non-CF healthy control, P < 0.01 versus wk 0 (ANOVA). (C) Left Immunoblot detection of CFTR in whole
lysates. ACTB was used as loading control. Representative blot of one non-CF control and 1 out of 3 patients with CF (No. 10 of Table 1) analyzed before and after
8 and 12 wk of treatment in vivo. Right, densitometric measurement of CFTR expressed as ratio of Band C /B and as percentage non-CF healthy control normalized
to ACTB levels. Mean§ SD of triplicates of independent experiments; ##P< 0.01 compared to non-CF healthy control, P< 0.01 versuswk 0 (ANOVA). (C) Assess-
ment of iodide efflux by a fluorescence assay (SPQ) upon stimulation with Fsk plus IBMX in freshly isolated nasal epithelial cells collected from patient No 10
before treatment and after 8 and 12 wk of treatment in vivo.
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Nasal brushing
Freshly isolated brushed
nasal epithelial cells were col-
lected by nasal brushing, as pre-
viously described,27 from 10
F508del-CFTR homozygous CF
patients at wk 0, 4, 8, 12 and
from 5 non-CF healthy volun-
teers recruited from staff at the
same time points. Both patients
and healthy volunteers gave
written informed consent.
After nostril washing to
remove mucus, cytological
brushes (Robimpex,
MO11157) were used to scrape
the mid part of the inferior tur-
binate from both nasal nostrils.
Brushes with cells were immedi-
ately transferred into RPMI
1640 medium (Invitrogen) con-
taining 1% penicillin-strepto-
mycin (Lonza, 17-602E), in 15-
ml sterilized tubes. The tubes
were incubated at 37 C for 2 h
on a thermo shaker, to remove
all cell from brushes, the
brushes were then removed and
the cells centrifuged at 800 x g
(2000 rpm) for 20 min. The
supernatant fractions were dis-
carded and the cell pellet treated
with 150 mL of trypsin-versene
(EDTA) solution (Lonza, 17-
161) for 4 min at 37 C to dis-
aggregate possible cell clusters.
Trypsin solution was inacti-
vated by adding 3 ml of serum-
free Bronchial Epithelial cell
Growth Medium BEGM (Clo-
netics, Lonza, CC3170). After
centrifugation at 800 x g
(2000 rpm) for 10 min, cells
were placed in CELLC T 25
flasks (Sarstedt Ltd, CS300)
with 10 ml of BEGM medium.
Nonspecific epithelial cells were
removed during the daily cell
washing and medium changes.
Counterstaining with anti-
KRT18/cytokeratin-18 (CK-
18; Abcam, ab52948) antibody
was used to confirm epithelial cell
purity, and with anti-CD3C,
(Abcam, ab5690), CD4C
(Abcam, ab51312) or CD19C
Figure 7. Effects of in vivo treatment on BECN1 and SQSTM1 protein levels in nasal brushing from F508del-CFTR
homozygous patients. (A) Effects of treatment on BECN1 (left) and SQSTM1 (tight) protein levels in freshly isolated
nasal epithelial cells of patients No. 5, 6 and 10 of Table 1. The values are expressed as percentage of non-CF
healthy control (considered as 100% of value). Mean § SD of triplicates of independent experiments per each
patient’s sample; ##p < 0.01 compared to non-CF healthy control, P < 0.05 and P < 0.01 versus wk 0 (ANOVA).
(B and C) Representative blot of 1 patient (No. 10 of Table 1) out of 3 patients analyzed. (B) Western blot analysis of
cell lysates and immunoblot with anti-BECN-1 (Abcam); (C) Western blot analysis of insoluble and soluble protein
fractions and immunoblot with anti-SQSTM1 (Sigma Aldrich). ACTB was used as negative marker of the insoluble
protein fraction and as loading control of the experiment. Bottom, densitometric measurement of (B) BECN-1 and
(C) SQSTM1 levels expressed as percentage of non-CF healthy control. Mean § SD of triplicates of independent
experiments; ##P< 0.01 compared to non-CF healthy control, P< 0.05 and P< 0.01 versus wk 0 (ANOVA).
www.landesbioscience.com 2067Autophagy
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 D
un
de
e] 
at 
08
:37
 27
 Ja
nu
ary
 20
16
 
(Abcam, ab25232) 1:500 antibodies to exclude the presence of lim-
phocytes and inflammatory cells. At 60% of confluence the cells
were passed in new flasks and Trypan blue staining exclusion test
was used to establish total viable cell number. Cells were also stained
with anti-Pan-cytokeratin (Sigma Aldrich, C5992) 1:500 and
MUC5AC (Abcam, ab3649) or MUC3B (Abcam, ab85006) 1:200
antibodies to exclude mucipar differention. The analysis of freshly
isolated nasal cells was performed after 48 h of seeding to ensure the
depletion of nonspecific debris and minimal contamination from
other mixed cell populations.
In vivo analysis
Samples were assessed for iodide efflux, cytokine expression,
and biochemical analysis before and after treatments at each
point through the study.
Ex vivo analysis
Nasal epithelial cells collected at the baseline time point (wk
0) were also cultured ex vivo until 60% confluence and then split.
The cells (maximum 3 passages) were treated with cysteamine
(250 mM; Sigma Aldrich, M9768) for 18 h and finally kept
untreated until 48 h in presence of medium alone or of medium
added with EGCG (80 mM; Sigma Aldrich, E4143) or with CX-
4945 (5 mM; SYNthesis Med Chem, SYN-1109).
Cell lines and treatments
CFBE41o-cells (F508del/F508del-CFTR) (kindly provided by
DC Gruenert) were grown in Transwells (Corning, 3470 or
3460, to seed 8 £ 104 or 3 £ 105 cells, respectively), and trans-
fected with F508del-CFTR at 37 C.
CFBE41o-cells were cultured in Minimum Essential Medium
Earle’s salt (200 mM L-glutamine, 10% fetal bovine serum, and
penicillin/streptomycin). CFBE41o- cells were grown in Trans-
wells under the normal condition. Briefly, 8 £ 104 or 3 £ 105
cells were seeded in 6.5-mm diameter or 12-mm diameter colla-
gen-coated Transwells, respectively, and grown until the RT
reached 800 to 1,000 V・cm2. Transwells with a pore size of
0.4 mm were used. Medium in both the apical and basolateral
chambers was changed every other day. Monolayers were immu-
nostained for OCLN/occludin (Abcam, ab31721) to confirm
polarization.27
Cells were incubated with cysteamine (250 mM) for 18 h and
then kept for the following 48 h with medium alone or medium
added with either EGCG (80 mM) or CX-4945 (5 mM) in the
presence or absence of CFTRinh-172 (20 mM; Sigma Aldrich,
C2992). Cycloheximide (CHX, 100 mg ml¡1; Sigma Aldrich,
C4859) was added during the last 8 h of incubation to inhibit
protein neosynthesis, as previously described.27,31 The MTT
(5 mg ml¡1; Sigma Alrich, M5665) assay was performed to ver-
ify the CHX toxicity, as previously described.27
Plasmids and transfection
The pcDNA3.1DF508-CFTR expression vector (PRIMM,
Milan), was used for transfection experiments in CFBE41o- cell
lines, as described.27 Cells were transfected with pcDNA3.1
DF508-CFTR or expression vectors, by Lipofectamine 2000 (Invi-
trogen, 11668-027) according to the manufacturer’s instructions.
Mice and treatments
CF mice homozygous for the F508del-Cftr in the 129/FVB
outbred background (Cftrtm1EUR, F508del, FVB/129, abbrevi-
ated CftrF508del) were obtained from Bob Scholte, Erasmus Medi-
cal Center Rotterdam, The Netherlands (CF-coordinated action
program EU FP6 LSHM-CT-2005-018932). These studies and
procedures were approved by the local Ethics Committee for
Animal Welfare (IACUC N 553 and 582) and conformed to
the European Community regulations for animal use in research
(2010/63 UE). Young adult heterozygous mice were housed in
static isolator cages at the animal care specific pathogen-free facil-
ity of Charles River (Calco, Italy). The newborn mice aged 15 d
old (n D 297 mice) were administered via gavage with cyste-
amine (60 mg/kg in 100 ml saline/day) or 100 ml saline/d for 5
Figure 8. Effects of treatment on sweat chloride levels in vivo in F508del-
CFTR homozygous patients. (A) Sweat chloride levels (mmol per liter) in
all the enrolled CF patients before and after 4, 8 and 12 wk of treatment
and after 4 (wk 16) and 8 (wk 20) wk following drug withdrawal. Red
markers indicate mean values, #PD 0.0029 vs wk 0. The dashed line indi-
cates 60 mmol/L. (B) Inverse correlation between percent of absolute
changes in sweat chloride levels and changes in rate of iodide efflux
(expressed as percent of healthy controls) in nasal brushing after 8 wk of
treatment in all the enrolled CF patients. The Spearman r D -0.883, P D
0.001.
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consecutive d/wk for 5 wk. Mice were weighed on the first and
last d of the treatment.
Seventy adult (10- to 12-wk-old) CftrF508del mice were orally
administered with vehicle alone (n D 35) or cysteamine (n D 35)
(7 d, via gavage, 60 mg/kg in 100 ml saline/d). Thirty of the
CftrF508del mice cysteamine-treated group of mice were subse-
quently randomized as following. Mice (n D 5 per group) were
administered via gavage with vehicle or EGCG (150 mg/kg in
Figure 9. Effects of treatment on respiratory inflammation in vivo in F508del-CFTR homozygous patients. (A and B) TNF and CXCL8 transcript levels in
nasal brushing from all the enrolled CF patients before (wk 0) and after 4, 8 and 12 wk of treatment. (A) TNF, ##P D 0.026 and (B) CXCL8, ##P D 0.023 vs
wk 0. (C and D) TNF and CXCL8 protein levels (pg/ml) in the sputum before treatment (wk 0) and after 4, 8 and 12 wk of treatment. (C) TNF, ##P D
0.0019, #P D 0.016 as compared to wk 0. (D) CXCL8, #P D 0.024 vs wk 0. (E) Correlation between absolute changes in TNF protein levels (pg/ml) in the
sputum after 12 wk of treatment and in sweat chloride levels (mmol/L) after 4 wk of treatment. The Spearman r D 0.770, P D 0.009.
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100 ml saline/day) for 10, 20, or 30 d after the cessation of cyste-
amine treatment.
At the end of the treatment, mice were anesthetized with
Avertine (tribromoethanol, 250 mg/kg; Sigma Aldrich, T48402)
and a segment of tail was collected for genotyping. Mice were
then sacrificed and lungs and intestines collected for analysis.
Immunoblot analysis
The proteins were obtained from both treated and untreated
nasal epithelial cell and CFBE41o- cell lines as well as from either
mouse intestinal or lung homogenates and the amounts of pro-
teins were determined by a Bio-Rad protein assay to ensure equal
protein loading before immunoblot analysis. For freshly isolated
cell, after 48 h seeding, a large amount (120 mg) of protein was
loaded to detect CFTR protein. An amount of 70 mg of protein
from ex-vivo nasal epithelial cells, CFBE41o- cells and samples
from mouse tissue homogenates were loaded in each lane. West-
ern blot analysis was performed with antibodies against the fol-
lowing proteins: SQSTM1, (Sigma Aldrich, 108k4767) 1:1000,
BECN1 (Abcam, ab58878) 1:1000, CFTR clone CF3 (Abcam,
ab2784) 1:1000, CFTR clone M3A7 (Abcam, ab4067) 1:500,
CFTR clone H-182 (Santa Cruz Biotechnology, sc-10747)
1:500, FLOT1/Flotillin-1 clone C-2 (Santa Cruz Biotechnology,
sc-74576) 1:1000, ACTB/b-actin (Cell Signaling Technology,
4970) 1:1000, TUBA/a-b tubulin (Cell Signaling Technology,
2148) 1:1000. The densitometric analysis was performed by
ImageJ software and each data point was expressed as the mean
§ SD of triplicate of independent experiments.
Soluble and insoluble protein fractions
Cells were lysed in buffer containg 50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 0.5% Nonidet P40 (Sigma Aldrich, NP405),
5 mM EDTA, 1 mM phenylmethylsulphonyl fluoride (Sigma
Aldrich, P7626), 50 mM NaF (Sigma Aldrich, S1504), 10 mg
ml¡1 leupeptin (Sigma Aldrich, L5793) and 10 mg ml¡1 aprotinin
(Sigma Aldrich, A3428) supplemented with protease inhibitors
(Sigma Aldrich, P8340) and centrifuged at 9,000 x g at 4 C for
20 min. After centrifugation the soluble (supernatant) and insolu-
ble (pellet) fractions were used in western blot analysis with anti-
SQSTM1 antibody. The pellet insoluble in Nonidet P40 was dis-
solved 5 times in sample buffer, boiled at 95 C for 5 min and
resolved on a polyacrylamide gel. The densitometric analysis was
performed by ImageJ software and each data point was expressed as
the mean§ SD of triplicate of independent experiments.
Cell surface biotinylation assay and membrane fractionation
Cell-surface proteins were biotinylated and the plasma mem-
brane fraction was collected as previously described.26, 27 Cell-
surface proteins were biotinylated using sulfosuccinimidyl-6-
(biotinamido) hexanoate (sulfo-NHS-LC-Biotin; Pierce, 21335,
dissolved at 1 mg ml¡1 in PBS (GIBCO, 18912-014, pH 8.2),
as described.27 Cells were homogenized with a Potter-Elvehjem
pestle and centrifuged at 2300 x g for 15 min at 4 C. Superna-
tant fractions that contain the cytoplasmic and plasma membrane
fractions were centrifuged 1 h at 16,000 x g at 4 C; the pellet
was the intact membrane and was solubilized in Buffer A
(20 mM Tris-HCl, pH 7.4, 2 mM EDTA, 20 mM 2-mercap-
toethanol, 1X PMSF, 1 mg ml¡1 inhibitor protease cocktail
(Sigma Aldrich, P8340) C1% Triton X-100 (Sigma Aldrich, X-
100-RS) and centrifuged 1 h at 60,000 x g in the ultracentrifuge.
The supernatant fractions were collected as plasma membrane
fraction. Equivalent amounts of protein (500 mg) were used for
streptavidin-agarose affinity isolation (Pierce, 20349). Biotiny-
lated proteins of plasma membrane fraction were immunoblotted
against CFTR (clone CF-3, or M3A7) or FLOT1. The densito-
metric analysis was performed by ImageJ software and each data
point was expressed as the mean § SD of triplicate of indepen-
dent experiments.
Measurement of rectal potential difference
RPD was measured with a protocol similar to that for nasal
potential difference measurements in humans, as described.39,70
Mice were anesthetized with tribromoethanol (250 mg/kg).
RPD was sensed with a digital volthometer inserted for about
2 cm in the rectum. Potentials were measured with respect to a
subcutaneous 1 M NaCl-filled needle. A second rectal tube was
used for continouous perfusion of drug adiministration into the
rectum. The Cl¡ containing solution had the following composi-
tion: 145 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2,
10 mM HEPES (Sigma Aldrich, H3375), 0.1 mM amiloride
(Sigma Aldrich, 1019701), at a final pH 7.4. The Cl¡ free solu-
tion had the following composition: 145 mM sodium gluconate
(Sigma Aldrich, 52054), 4 mM potassium gluconate (Sigma
Aldrich, 1550001), 4 mM calcium gluconate (Sigma Aldrich,
C0300000), 1 mM magnesium gluconate (Sigma Aldrich,
G9130), 10 mM HEPES, 0.1 mM amiloride, at a final pH 7.4.
Assessment of CFTR function in freshly isolated
nasal epithelial cells from F508del-CFTR
homozygous patients
Freshly isolated nasal cell were allowed to seed for 48 h and
then analyzed before and after ex vivo culture. The analysis of
iodide efflux was performed in nasal cells, by the iodide-sensitive
fluorescent indicator, SPQ (Molecular Probes/Invitrogen,
M440), as previously described.27
Iodide efflux
The iodide-sensitive fluorescent indicator SPQ (Molecular
Probes/Invitrogen, M440) was introduced into the cells in a hypo-
tonic solution of iodide buffer (in mM: 130 NaI [Sigma Aldrich,
229911], 4 KNO3 (Sigma Aldrich, P6030), 1 Ca(NO3)2 (Sigma
Aldrich, 31218), 1 Mg(NO3)2 (Sigma Aldrich, 6384), 10 glucose
and 20 HEPES, pH 7.4) diluted 1:1 with water and containing a
final concentration of 10 mM SPQ. Cells were loaded for 20 min
at 37 C in a humidified chamber with 5% CO2. The SPQ-loaded
cells were then mounted on a LSM510 Meta confocal microscope
(Zeiss, Milan, Italy) with a 37 C heated stage and perfused with
iodide buffer for 5 to 8 min. Changes in CFTR-mediated SPQ
fluorescence were monitored at the 445 nm wavelength in response
to excitation at 340 nm during perfusion at 37 C in nitrate buffer
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replaced with 130 mM NaNO3 (Sigma Aldrich, S8170) with
20 mM forskolin (Fsk; Sigma Aldrich, F6886) plus 100 mM
IBMX (Sigma Aldrich, I5879) and fluorescence intensity measured
for a further 10 to 12 min. Signals were collected at 30-sec interval.
For each minute the average of the fluorescence intensity was mea-
sured from 50 cells for population per coverslip and the peak of
iodide efflux rate (usually after Fsk plus IBMX adding) of cells was
calculated in accordance with the Stern-Volmer relationship as
follows:
.Fo=F/¡ 1DKCQ
where F is the observed fluorescence, Fo is the fluorescence in the
absence of a quenching anion, CQ is the concentration of the
quenching anion, and K is the Stern-Volmer quench constant.
The rates were calculated using SigmaPlot Version 7.1 for each
mean fluorescence trace for each time point generated from the 50
cells examined per population per coverslip. 71-75
Real-time and reverse-transcription PCR analysis
The analysis was performed as previously described.29,76 Total
RNA was extracted with the RNeasy Mini Kit (Qiagen, 74104)
from mouse lung homogenates and from nasal brushing of CF
patients.
Mouse: The mRNA was reverse transcribed with a Super-
ScriptTM III First Strand Synthesis System (Promega, A5001).
Quantitative RT-PCR was performed with an iCycler iQ Multi-
color Real-Time PCR Detector (Bio-Rad, Milan, Italy) with iQ
TM SYBR Green supermix (Five Prime, 2900217). The relative
amounts of mRNA were calculated by using the comparative Ct
method. Real-time RT-PCR analyses were executed for evaluat-
ing the efficiency of expression. Thermocycling consisted of an
initial polymerase activation step at 98C for 5 min, and amplifi-
cation was performed with 35 cycles of 95C for 15 sec, 68C
for 10 sec and 72C for 20 sec with data acquisition at this stage
and the reaction finished by the built in melt curve.
The sequences of mouse primers were: Tnf forward 50-CCAC-
CACGCT CTTCTGTCTA-30 and reverse 50-AGGGTCTGGG
CCATAGAACT-30;
Cxcl2 forward 50-GCTGGCCACC AACCACC-30 and
reverse 50AGCGAGGCAC ATCAG GTACG-30; Gapdh
forward 50-GTGATGCTGG GTG-30 and reverse 50-
CAGTCTTCTG AG-30. Expression levels of genes were normal-
ized to Gapdh levels in the same sample.
Human: The mRNA was reverse transcribed with a Super-
ScriptTM III First Strand Synthesis System. Quantitative RT-
PCR was performed with an iCycler iQ Multicolor Real-Time
PCR Detector (Bio-Rad) with iQ TM SYBR Green supermix.
Thermocycling consisted of an initial polymerase activation step
at 95C for 5 min, amplification was performed with 40 cycles
of 95C for 15 sec, 60C for 10 sec and 72C for 20 sec with
data acquisition at this stage and the reaction finished by the built
in melt curve.
The sequences of human primers were: TNF forward 50-
CGAGTCTGGG CAGGTCTACT TT-30 and reverse 50-
AGAGGTTGAG GGTGTCTGAAG G-30; CXCL8 forward 50-
ATG ACTTCCAAGC TGGCCGTGGC T-30 and reverse 50-
TCTCAGCCCT CTTCAAAAAC TTCT-30; for ACTB forward
50-CCGATCCACA CGGAGTACTT G-30 and reverse: 50-
GGCACCCAGC ACAATGAAG-30. Expression levels of genes
were normalized to ACTB levels in the same sample.
ELISA
Sputum samples were diluted 1:2 with PBS and digested with
1 U/ml of DNAse (Sigma Aldrich, D4263) for 4 h at 37C. The
supernatant fractions were collected and stored at -80 C until
usage. The samples were then centrifuged at 800 x g for 10 min
and the supernatants used to measure TNF and CXCL8 levels by
ELISA. ELISA analysis was performed using standard ELISA kits
(R&D Systems, STA00C for TNF and S8000C for CXCL8),
according to the manufacturer’s instructions, as previously
reported.26,77 Samples were read in triplicate at 450 nm in a
Microplate Reader (BioRad, Milan, Italy) using Microplate
Manager 5.2.1 software. Values were normalized to protein con-
centration evaluated by Bradford analysis.
Inhibition of protein kinase CSNK2
Recombinant CSNK2, either CSNK2A, the a subunit or the
CSNK2A2-CSNK2B2 (a2b2) holoenzyme, was obtained as
described,50 and incubated for 10 min at 37C in a final volume
of 25 ml containing 50 mM Tris-HCl, pH 7.5, 100 mM NaCl,
12 mM MgCl2, 100 mM synthetic peptide substrate
RRRADDSDDDDD (in house synthesized) and 20 mM [33P-
ATP] (1000 to 2000 cpm/pmol). The reaction was stopped by
ice cooling and absorption on phospho-cellulose p81 paper
(Whatman, 369-8915). Papers were washed 3 times with
75 mM phosphoric acid, dried, and counted in a scintillation
counter. IC50 values represent the mean of 3 independent experi-
ments with the SD not exceeding 10%.
In situ detection of TGM2 enzyme activity
TGM2 activity in nasal epithelial cells was detected as
previously reported.26,30 Detailed methods are reported in
Supplemental Materials.
Statistical analysis
Categorical variables are presented as number (%) and contin-
uous variables as mean (SD) when normally distributed or
median (IQR) when not.
Mice. All laboratory tests on mice were performed at least in
triplicate.
Survival analysis was performed using the Kaplan-Meier
method to evaluate the effect of cysteamine on mouse survival.
Log-rank test was used to check statistical significance of differen-
ces in survival.
Between-group comparisons were evaluated by the unpaired
Student t test or one-way analysis of variance (ANOVA), and
www.landesbioscience.com 2071Autophagy
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 D
un
de
e] 
at 
08
:37
 27
 Ja
nu
ary
 20
16
 
post hoc comparisons were made using Tukey-Kramer test, when
appropriate. We set the level of significance at P< 0.05. Analyses
were carried out with SPSS 12 software.
Humans. The effects of treatment in CF patients were ana-
lyzed by repeated measures ANOVA to compare the means of
the laboratory and clinical variables measured at different times
of treatment and during the follow-up period: wk 8 vs baseline
(wk 0), wk 12 vs wk 0 for each variable; wk 16 vs wk 12 for sweat
test, FEV1% and FEF25-75%; wk 20 vs wk 12 and wk 20 vs wk 0
only for sweat test.
According to Sidak correction for multiple comparisons,78
each comparison was considered significant if P values (for the 2-
tailed test) were less than , were a is the overall type I error proba-
bility and n is the number of comparisons. Therefore, with an
overall a D 0.05 and n D 5, the significance threshold for each
comparison is 0.01; when n D 3, the threshold for each compari-
son is 0.017 and when n D 2, the threshold for each comparison
is 0.025; with an overall a D 0.01 the thresholds for each com-
parison are 0.002, 0.003, 0.005 respectively.
All data processing and analyses were carried out with SAS sta-
tistical software (version 9.2; SAS Institute, Cary, NC, USA).
In vitro experiments
Data are analyzed as previously reported.31 Data distribution
was analyzed for normality and statistical analysis performed
using the one-way ANOVA. Significant differences are indicated
in the figures. All data were obtained from independent measure-
ments. Data manipulations were carried out with SPSS 12
software.
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